Author: Lai, Samuel K.; McSweeney, Morgan D.; Pickles, Raymond J.
Title: Learning from past failures: Challenges with monoclonal antibody therapies for COVID-19 Cord-id: q5nws0q8 Document date: 2021_1_10
ID: q5nws0q8
Snippet: COVID-19, the disease caused by infection with SARS-CoV-2, requires urgent development of therapeutic interventions. Due to their safety, specificity, and potential for rapid advancement into the clinic, monoclonal antibodies (mAbs) represent a highly promising class of antiviral or anti-inflammatory agents. Herein, by analyzing prior efforts to advance antiviral mAbs for other acute respiratory infections (ARIs), we highlight the challenges faced by mAb-based immunotherapies for COVID-19. We pr
Document: COVID-19, the disease caused by infection with SARS-CoV-2, requires urgent development of therapeutic interventions. Due to their safety, specificity, and potential for rapid advancement into the clinic, monoclonal antibodies (mAbs) represent a highly promising class of antiviral or anti-inflammatory agents. Herein, by analyzing prior efforts to advance antiviral mAbs for other acute respiratory infections (ARIs), we highlight the challenges faced by mAb-based immunotherapies for COVID-19. We present evidence supporting early intervention immediately following a positive diagnosis via inhaled delivery of mAbs with vibrating mesh nebulizers as a promising approach for the treatment of COVID-19.
Search related documents:
Co phrase search for related documents- active mechanism and acute respiratory: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date